Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2)

被引：0
|
作者：
Merriman, Joseph
Parikh, Kinjal
Tantravahi, Srinivas Kiran
Straubhar, Alli M.
Agarwal, Archana M.
Sendilnathan, Arun
Van Atta, Joan
Batten, Julia A.
Grossmann, Kenneth F.
Samlowski, Wolfram E.
Stenehjem, David D.
Agarwal, Neeraj
机构：
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[2] Univ Utah, Dept Pathol & ARUP Labs, Salt Lake City, UT USA
[3] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[4] Univ Utah, Pharmacotherapy Outcomes Res Ctr, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.4577
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4577
引用
收藏
页数：1
相关论文
共 50 条
  • [41] High-dose IL-2 associated with improved response in renal cell carcinoma patients
    不详
    ONCOLOGY-NEW YORK, 2001, 15 (09): : 1138 - 1138
  • [42] High-dose interleukin-2 immunotherapy is safe for patients with metastatic renal cell carcinoma on dialysis
    Brusky, JP
    Gailani, F
    Pathak, A
    Patel, H
    Aboseif, S
    BJU INTERNATIONAL, 2006, 97 (02) : 279 - 280
  • [43] Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
    Buchbinder, Elizabeth I.
    Dutcher, Janice P.
    Daniels, Gregory A.
    Curti, Brendan D.
    Patel, Sapna P.
    Holtan, Shernan G.
    Miletello, Gerald P.
    Fishman, Mayer N.
    Gonzalez, Rene
    Clark, Joseph I.
    Richart, John M.
    Lao, Christopher D.
    Tykodi, Scott S.
    Silk, Ann W.
    McDermott, David F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [44] Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
    Ajjai Alva
    Gregory A. Daniels
    Michael K. K. Wong
    Howard L. Kaufman
    Michael A. Morse
    David F. McDermott
    Joseph I. Clark
    Sanjiv S. Agarwala
    Gerald Miletello
    Theodore F. Logan
    Ralph J. Hauke
    Brendan Curti
    John M. Kirkwood
    Rene Gonzalez
    Asim Amin
    Mayer Fishman
    Neeraj Agarwal
    James N. Lowder
    Hong Hua
    Sandra Aung
    Janice P. Dutcher
    Cancer Immunology, Immunotherapy, 2016, 65 : 1533 - 1544
  • [45] Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
    Alva, Ajjai
    Daniels, Gregory A.
    Wong, Michael K. K.
    Kaufman, Howard L.
    Morse, Michael A.
    McDermott, David F.
    Clark, Joseph I.
    Agarwala, Sanjiv S.
    Miletello, Gerald
    Logan, Theodore F.
    Hauke, Ralph J.
    Curti, Brendan
    Kirkwood, John M.
    Gonzalez, Rene
    Amin, Asim
    Fishman, Mayer
    Agarwal, Neeraj
    Lowder, James N.
    Hua, Hong
    Aung, Sandra
    Dutcher, Janice P.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (12) : 1533 - 1544
  • [46] Phase II trial of high-dose interleukin-2 (IL-2) and stereotactic radiation therapy (SABR) for metastatic clear cell renal cell carcinoma (ccRCC): Interim analysis.
    Hannan, Raquibul
    Ishihara, Dan
    Louder, Kristi
    Ahn, Chul
    Margulis, Vitaly
    Arriaga, Yull Edwin
    Courtney, Kevin Dale
    Timmerman, Robert D.
    Brugarolas, James
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [47] Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Johannes Vieweg
    Nature Clinical Practice Oncology, 2005, 2 : 192 - 193
  • [48] Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Vieweg, J
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (04): : 192 - 193
  • [49] A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
    Buchbinder, Elizabeth I.
    Gunturi, Anasuya
    Perritt, Jessica
    Dutcher, Janice
    Aung, Sandra
    Kaufman, Howard L.
    Ernstoff, Marc S.
    Miletello, Girald P.
    Curti, Brendan D.
    Daniels, Gregory A.
    Patel, Sapna P.
    Kirkwood, John M.
    Hallmeyer, Sigrun
    Clark, Joseph I.
    Gonzalez, Rene
    Richart, John M.
    Lutzky, Joe
    Morse, Michael A.
    Sullivan, Ryan J.
    McDermott, David F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [50] High-dose interleukin-2 therapy for metastatic renal cell carcinoma: A contemporary experience
    Aboumohamed, Ahmed A.
    Yarlagadda, Naveen
    Creighton, Terrance
    Mehedint, Diana
    Attwood, Kristopher
    Kauffman, Eric
    George, Saby
    Khushalani, Nikhil I.
    Pili, Roberto
    Schwaab, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345